Immunologic Factor – Page 9

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

3 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

3 months ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection

Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results

3 months ago talkbio0Tagged alpha-synuclein antibody, Biological Markers, Clinical Trials, disease-modifying treatment, PADOVA study, Parkinson 's disease, Pasadena, Phase 3 Clinical Trials, Prasinezumab, Prothena, Roche (company)

Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

3 months ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

3 months ago talkbio0Tagged Bharat, biotech, GMMA platform, low, Microbicides, middle-income countries, Resistance (Psychotherapeutic), Shigella Infections, Shigella Vaccines, SmithKline Beecham, vaccine licensing

GSK; Bharat Biotech; Shigella vaccine; altSonflex1-2-3; vaccine licensing; Shigellosis; GMMA platform; antimicrobial resistance; low and middle-income countries

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

3 months ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

All innuendo and conspiracy: RFK Jr.’s vaccine advisory overhaul undermines vaccine confidence, experts say

3 months ago talkbio0Tagged ACIP, advisory, conspiracy, overhaul, public health medicine (field), RFK Jr., Self Confidence, Vaccines

RFK Jr.; vaccine advisory; ACIP; public health; conspiracy; confidence; overhaul

AstraZeneca’s Calquence Combo Approved for First-Line CLL in EU

3 months ago talkbio0Tagged Amplify trial, Approved, AstraZeneca, BTK inhibitor, Calquence, Chronic Lymphocytic Leukemia, EU, First line treatment, obinutuzumab, venetoclax

AstraZeneca; Calquence; EU approval; chronic lymphocytic leukaemia; first-line treatment; venetoclax; obinutuzumab; BTK inhibitor; Amplify trial

Otsuka’s Phase 3 IgAN Win with Sibeprenlimab Shakes Vera’s Stock

3 months ago talkbio0Tagged IGA Glomerulonephritis, Kidney Diseases, Otsuka, Priority Review, Proteinuria, Sibeprenlimab, stock drop, United States Food and Drug Administration, UPCR, vera

Otsuka; sibeprenlimab; IgA nephropathy; phase 3 trial; proteinuria reduction; Vera Therapeutics; stock drop; kidney disease; UPCR; FDA Priority Review

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

3 months ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment